Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.200 -0.050 (-4.00%)
Streaming Delayed Price Updated: 10:41 AM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Proposed Public Offering of Common Stock
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally ↗
Lexicon Pharmaceuticals (LXRX) Q3 2025 earnings crush estimates with a massive revenue beat, driven by its Novo Nordisk partnership. The stock rose on the strong results and promising pipeline... 
Via Chartmill
News headline image
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1... 
Via Benzinga
Topics Stocks
News headline image
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.